What is pseudohyperkalaemia and how is it identified?

Pseudohyperkalaemia is an artefactually elevated serum potassium result caused by in vitro release of intracellular potassium from erythrocytes into serum — most commonly from haemolysis during or after venepuncture, but also from delayed centrifugation, prolonged tourniquet use, vigorous tube mixing, or extreme thrombocytosis and leucocytosis during clot formation. It is identified by a haemolysis index flag on the laboratory report or visible pink discolouration of the serum. Any elevated potassium result must be assessed for haemolysis before clinical action — a haemolysed elevated potassium specimen must be recollected under optimal conditions before treatment decisions are made.

Which medications require serum potassium monitoring?

Thiazide and loop diuretics cause potassium wasting and hypokalaemia — monitoring is mandatory at initiation and after dose changes. ACE inhibitors, ARBs, and mineralocorticoid receptor antagonists (spironolactone, eplerenone) reduce renal potassium excretion and cause hyperkalaemia — particularly in CKD, diabetes, and with concurrent NSAID use. Digoxin toxicity is potentiated by hypokalaemia — potassium must be maintained in the upper reference range during digoxin therapy. Trimethoprim, calcineurin inhibitors, and heparin also elevate potassium through distinct mechanisms.

Why must potassium be corrected before repletion in hypokalaemia?

Hypomagnesaemia is the most common cause of refractory hypokalaemia — magnesium is required for normal renal potassium conservation via ROMK channel regulation, and potassium repletion fails to correct hypokalaemia while magnesium deficiency persists. Serum magnesium must be assessed and corrected before or alongside potassium repletion in all patients with moderate-to-severe hypokalaemia or when hypokalaemia fails to respond to standard replacement therapy.

How does acidosis affect serum potassium?

Metabolic and respiratory acidaemia drives potassium out of cells in exchange for hydrogen ions — as a rough approximation, serum potassium rises by approximately 0.5–0.6 mEq/L for each 0.1 unit decrease in arterial pH in mineral acid acidosis. This redistribution means that a patient in DKA can present with normal or elevated serum potassium despite profound total body potassium depletion — as insulin therapy and acidosis correction drive potassium back into cells, serum potassium falls rapidly and may reach critically low levels without anticipatory replacement.

Is fasting required before a serum potassium test?

No. Fasting is not required for serum potassium. Pre-analytical handling technique — avoiding prolonged tourniquet time, centrifuging within 30 minutes, not shaking the tube — is far more critical to result accuracy than fasting status.

How long does it take to receive serum potassium results from Access Medical Laboratories?

Results are typically available within 1–2 business days from specimen receipt at the Access Medical Laboratories processing laboratory. Potassium is a high-throughput automated chemistry measurement. Critical values — typically below 2.5 mEq/L or above 6.0–6.5 mEq/L — are reported urgently to the ordering practitioner by phone per CLIA critical value notification requirements.

What is the difference between serum and plasma potassium?

Serum potassium is measured after the blood has clotted in an SST tube — during clotting, platelets and leucocytes release a small amount of potassium, making serum potassium approximately 0.3–0.5 mEq/L higher than plasma potassium. Plasma potassium (heparin tube) bypasses clot formation and is the preferred specimen when pseudohyperkalaemia from extreme thrombocytosis or leucocytosis is suspected. A plasma potassium that is normal alongside an elevated serum potassium in a visually non-haemolysed specimen confirms in vitro cellular release as the source of the discrepancy.

BML-MET-010metabolic diabetesUSA

Potassium, Serum

Q: What does the serum potassium test measure and why is it clinically important?

Serum potassium measures the concentration of potassium in the extracellular fluid — the fraction outside cells — which, despite representing only approximately 2% of total body potassium, is the dominant determinant of cardiac membrane potential and neuromuscular excitability. Deviations in either direction carry significant cardiac arrhythmia risk: hypokalaemia predisposes to ventricular ectopy and torsades de pointes; hyperkalaemia impairs cardiac conduction, producing a progressive ECG deterioration that can culminate in ventricular fibrillation or asystole at severe levels.

The Serum Potassium test quantifies extracellular potassium concentration — the dominant determinant of cardiac membrane potential and neuromuscular excitability — in serum. It is a mandatory monitoring parameter for diuretic therapy, ACE inhibitor and ARB use, CKD management, adrenal disease evaluation, and cardiac arrhythmia risk stratification.

Biomarkers

Blood (serum)

Sample

1–2 business days

Turnaround

No — fasting is not required for serum potassium. However, collect before any potassium supplementation infusion or high-potassium meal if a true baseline is needed. The pre-analytical handling protocol below is far more clinically critical than fasting status for this analyte.

Fasting

What is the Serum Potassium test?

The Potassium Serum test quantifies the concentration of potassium in the extracellular fluid compartment as represented by serum, providing the definitive measurement of serum potassium status for clinical decision-making across a broad range of acute, chronic, and preventive clinical contexts. It is among the most frequently ordered laboratory tests in clinical medicine — ordered as a standalone electrolyte, as a component of comprehensive metabolic panels, and as a mandatory safety monitoring parameter for a wide range of medications that alter potassium homeostasis. Potassium occupies a unique position among clinical chemistry analytes in that it is simultaneously a high-throughput routine electrolyte and a potentially life-critical measurement requiring urgent action at its extremes. The pre-analytical vulnerability of the serum potassium measurement — specifically its susceptibility to artefactual elevation from erythrocyte potassium release during haemolysis — places it among the most pre-analytically demanding of routine clinical chemistry tests, and a significant proportion of hyperkalaemia results encountered in clinical practice are pseudohyperkalaemia from haemolysed specimens rather than true potassium elevation. This distinction has direct patient safety implications — unnecessary withholding of medications, inappropriate emergency treatment, and avoidable patient anxiety are common consequences of failure to recognise and appropriately retest haemolysed hyperkalaemic results.

What does the Serum Potassium test measure?

K⁺(Potassium, Serum)

Range: 3.5–5.1 mEq/L (3.5–5.1 mmol/L) # REVIEWER FLAG: Confirm Access Medical Laboratories reference range for serum potassium — upper and lower limits vary slightly between laboratories (some use 3.5–5.0, others 3.5–5.3 mEq/L). Confirm whether Access Medical Laboratories applies age-stratified reference intervals — serum potassium is modestly higher in neonates and infants. Confirm critical value thresholds flagged on Access Medical Laboratories reports — most laboratories flag <2.5 mEq/L and ≥6.0–6.5 mEq/L as critical values requiring urgent clinical notification.Optimal: 3.8–4.5 mEq/L (functional medicine and cardiology optimal — this range is associated with the lowest risk of cardiac arrhythmia and all-cause mortality in population data; the lower end of the reference range [3.5–3.8 mEq/L] carries measurably increased cardiac event risk in patients with structural heart disease, digoxin use, or QT prolongation). # REVIEWER FLAG: The 3.8–4.5 mEq/L optimal is used in preventive cardiology and integrative practice but is not a universally standardised clinical guideline threshold — reviewer to confirm appropriate framing and whether cardiovascular outcome literature should be cited to support this range.mEq/L / mmol/L

Potassium is the principal intracellular cation — approximately 98% of total body potassium (approximately 3,500 mEq in a 70 kg adult) is contained within cells, maintained by the ubiquitous Na⁺/K⁺-ATPase pump at an intracellular concentration of approximately 140–150 mEq/L. Serum potassium reflects only the extracellular pool — approximately 2% of total body potassium — and is maintained within a remarkably narrow physiological range (3.5–5.1 mEq/L) through the integrated actions of renal potassium handling, aldosterone, insulin, catecholamines, and acid-base status. Aldosterone is the primary regulator of renal potassium excretion — acting on principal cells of the cortical collecting duct to upregulate luminal ENaC sodium channels and ROMK potassium channels, driving sodium reabsorption and potassium excretion coupled to the electrochemical gradient. Insulin and beta-2 adrenergic agonists promote cellular potassium uptake by stimulating Na⁺/K⁺-ATPase activity; acidaemia drives potassium out of cells in exchange for hydrogen ions, raising serum potassium; alkalaemia reverses this shift, lowering serum potassium. The resting membrane potential of excitable cells — cardiac myocytes and neurones — is determined by the ratio of intracellular to extracellular potassium, making serum potassium the dominant determinant of cardiac rhythm and neuromuscular function.

Serum potassium is one of the highest-stakes electrolyte measurements in clinical practice, with deviations in either direction carrying significant cardiac arrhythmia risk. Hypokalaemia — serum potassium below 3.5 mEq/L — hyperpolarises cell membranes, reducing excitability and predisposing to ventricular ectopy, torsades de pointes, and life-threatening ventricular fibrillation, particularly in patients with underlying cardiac disease, digoxin use, or QT prolongation. Hyperkalaemia — serum potassium above 5.1 mEq/L — depolarises cell membranes, impairing cardiac conduction and producing the characteristic ECG progression of peaked T waves, widened QRS, sine wave pattern, and ventricular fibrillation or asystole at severe levels. Serum potassium is the mandatory monitoring marker for a wide array of medications that alter potassium homeostasis — diuretics, ACE inhibitors, ARBs, mineralocorticoid receptor antagonists, digoxin, and immunosuppressants — and is a core component of renal function assessment, adrenal disease evaluation, and acid-base disorder characterisation. Pre-analytical integrity is the dominant clinical challenge — haemolysis from any cause elevates serum potassium artifactually (pseudohyperkalaemia), and this is the single most important interpretive caveat for any elevated potassium result.

Why is the Serum Potassium test ordered?

Diuretic therapy monitoring — thiazide and loop diuretics cause potassium wasting through increased renal potassium excretion in the distal tubule; baseline and serial potassium monitoring is mandatory during diuretic initiation and dose escalation to detect hypokalaemia requiring supplementation or diuretic modification
ACE inhibitor, ARB, and mineralocorticoid receptor antagonist monitoring — these agents reduce aldosterone-mediated renal potassium excretion and carry hyperkalaemia risk, particularly in patients with CKD, diabetes, or concurrent NSAID use; potassium must be checked within 1–2 weeks of initiation and after dose changes
Chronic kidney disease monitoring — impaired renal potassium excretion in CKD produces progressive hyperkalaemia risk proportional to the degree of renal function loss; serial potassium is a mandatory CKD management parameter alongside eGFR, bicarbonate, and haemoglobin
Hypokalaemia investigation — unexplained muscle weakness, cramps, fatigue, palpitations, constipation, or polyuria in a patient on diuretics or with known gastrointestinal losses (vomiting, diarrhoea, fistula) or suspected primary aldosteronism, where potassium quantification drives the diagnostic and treatment pathway
Hyperkalaemia investigation — serum potassium elevated on a prior result or screen, requiring confirmation of a non-haemolysed specimen before clinical action is taken, followed by assessment of the aetiology — renal impairment, medication effect, adrenal insufficiency, or redistribution from acidosis
Adrenal and aldosterone disorder evaluation — hypokalaemia in the context of hypertension is a cardinal feature of primary aldosteronism (Conn's syndrome), where potassium wasting from autonomous aldosterone excess produces sustained hypokalaemia; Addison's disease and hypoaldosteronism cause hyperkalaemia through impaired renal potassium excretion
Cardiac arrhythmia risk assessment and management — potassium is the primary electrolyte modifying cardiac membrane potential and arrhythmia risk; monitoring is mandatory in patients with QT prolongation, atrial fibrillation, heart failure, or those on anti-arrhythmic medications, digoxin, or QT-prolonging drugs
Diabetic ketoacidosis and hyperosmolar state management — DKA produces complex potassium shifts that require close serial monitoring; total body potassium is depleted in DKA despite often-normal or elevated serum potassium at presentation, with aggressive insulin therapy driving rapid intracellular potassium shift and precipitous hypokalaemia requiring anticipatory replacement

Sample collection and turnaround

Sample type

Blood (serum)

Fasting required

Collection method

Venipuncture at patient service centre

Turnaround

1–2 business days

Collection notes

Standard venipuncture into a serum separator tube (SST / gold top). Pre-analytical technique is the highest-priority consideration for potassium — the following must be observed: (1) apply the tourniquet for the minimum time necessary to locate the vein — release immediately after needle placement; (2) do not instruct the patient to repeatedly clench and unclench their fist; (3) use the smallest gauge needle compatible with adequate flow — excessive vacuum pressure causes haemolysis; (4) mix the SST tube by gentle inversion 5 times only — do not shake; (5) centrifuge within 30 minutes of collection — do not leave whole blood at room temperature; (6) separate and refrigerate serum promptly after centrifugation; (7) inspect the specimen visually for haemolysis before dispatch — pink or red discolouration of serum indicates haemolysis and the specimen must be recollected. Document on the requisition form: current diuretics, ACE inhibitors, ARBs, potassium-sparing agents, NSAIDs, immunosuppressants, digoxin, and insulin; known CKD stage; and any known potassium disorder. # REVIEWER FLAG: Confirm Access Medical Laboratories SST tube type, minimum volume, maximum time from collection to centrifugation, and refrigerated serum stability for potassium before publication. Confirm whether Access Medical Laboratories reports a haemolysis index alongside the potassium result on all specimens.

Specimen requirements

Minimum 0.5 mL serum. Centrifuge within 30 minutes of collection. Stable at 2–8°C for up to 5 days after separation. Do not freeze serum for potassium — freeze-thaw cycles cause cell membrane damage in any residual cellular material and may alter potassium values. # REVIEWER FLAG: Confirm minimum volume and stability data with Access Medical Laboratories.

What can affect Serum Potassium results?

elevatesHaemolysis — in vitro erythrocyte potassium release (pseudohyperkalaemia)

Erythrocytes contain intracellular potassium at approximately 105–150 mEq/L — 20–30 times the serum concentration. Any degree of haemolysis — whether from traumatic venepuncture, excessive needle vacuum pressure, vigorous tube mixing, prolonged tourniquet application, delayed centrifugation, or specimen transport trauma — releases erythrocyte potassium into serum, producing artefactually elevated potassium (pseudohyperkalaemia) that does not reflect the patient's true serum potassium. This is the most clinically significant pre-analytical interference in routine clinical chemistry. Even visually imperceptible haemolysis detectable only by the analyser's haemolysis index can elevate serum potassium by 0.3–0.5 mEq/L; grossly haemolysed specimens may show elevations of 1.0–2.5 mEq/L above true values. Any elevated potassium result must be assessed for haemolysis — if haemolysis is confirmed or the result is inconsistent with clinical status, the specimen must be recollected under optimal conditions before clinical action is taken.

elevatesProlonged tourniquet time and fist clenching during venepuncture

Prolonged tourniquet application (beyond 60 seconds) causes local tissue hypoxia and metabolic acidosis in the forearm, driving potassium out of muscle cells into the local venous blood — a mechanism that can elevate local potassium by 0.2–0.5 mEq/L in the collected specimen. Repeated fist clenching during venepuncture exacerbates this effect through increased forearm muscle metabolic activity. Standard venepuncture practice — tourniquet release promptly after needle placement, minimal patient fist-clenching — is essential for reliable potassium results.

elevatesDelayed centrifugation and prolonged cellular contact in unsealed tubes

In unsealed SST tubes at room temperature, intact erythrocytes continuously lose potassium through leakage as cellular ATP is depleted and Na⁺/K⁺-ATPase activity declines — a passive potassium efflux that progressively elevates serum potassium with time before centrifugation. SST tubes should be centrifuged within 30 minutes of collection to prevent this artefact. Specimens left uncentrifuged at room temperature for more than 1–2 hours can show potassium elevations of 0.5–1.5 mEq/L above true values.

elevatesExtreme leukocytosis and thrombocytosis (in vitro pseudohyperkalaemia)

In patients with markedly elevated white blood cell counts (>100 ×10³/µL, as in chronic lymphocytic leukaemia or blast crisis) or extreme thrombocytosis (>1000 ×10³/µL), in vitro potassium release from these cells during clot formation and centrifugation of serum tubes can produce pseudohyperkalaemia. This cause of pseudohyperkalaemia is suspected when potassium is elevated in a visually non-haemolysed specimen in a patient with known haematological malignancy and confirmed normal potassium on a concurrent plasma (heparin tube) specimen — because plasma potassium bypasses clot formation and cellular lysis. Requesting a plasma potassium alongside the serum result is the standard approach to investigate suspected in vitro pseudohyperkalaemia in these patients.

elevatesAcidaemia — metabolic and respiratory acidosis

Acidaemia drives potassium out of cells in exchange for hydrogen ions via electroneutral exchange — a buffering mechanism that protects intracellular pH at the cost of raising serum potassium. As a clinical approximation, serum potassium rises by approximately 0.5–0.6 mEq/L for each 0.1 unit decrease in pH in a pure mineral acid acidosis, though this relationship is less predictable in organic acidoses (lactic acidosis, DKA). Conversely, alkalaemia drives potassium into cells, lowering serum potassium. Acid-base status must always be assessed alongside potassium when interpreting values near the clinical action thresholds.

reducesInsulin, beta-2 agonists, and catecholamines

Insulin and beta-2 adrenergic receptor stimulation (from endogenous catecholamines or exogenous bronchodilators) each independently stimulate Na⁺/K⁺-ATPase, driving potassium into skeletal muscle, liver, and other cells and lowering serum potassium by 0.5–1.0 mEq/L acutely. These mechanisms underlie the therapeutic use of insulin (with glucose) and salbutamol as emergency temporising treatments for hyperkalaemia, and explain the potassium-lowering effects of high-dose beta-2 agonist therapy in asthma and COPD. Acute stress-related catecholamine release — from acute MI, trauma, or physiological stress — similarly lowers serum potassium and may contribute to the hypokalaemia commonly observed in myocardial infarction.

What do Serum Potassium results mean?

Elevated

Confirmed hyperkalaemia (serum potassium ≥5.1 mEq/L on a non-haemolysed specimen) requires immediate assessment of the degree and aetiology, alongside an ECG in all patients above 5.5–6.0 mEq/L or with cardiac symptoms. Mild hyperkalaemia (5.1–5.9 mEq/L): assess medications (ACE inhibitors, ARBs, potassium-sparing diuretics, NSAIDs, trimethoprim), renal function, and dietary potassium intake; review for concurrent acidosis. Moderate hyperkalaemia (6.0–6.4 mEq/L): urgent ECG, cardiac monitoring assessment, medication review, and dietary restriction pending renal assessment. Severe hyperkalaemia (≥6.5 mEq/L): medical emergency — urgent ECG, parenteral calcium for membrane stabilisation if ECG changes present, insulin-glucose, salbutamol, sodium bicarbonate for redistribution, and potassium elimination (diuresis, cation exchange resin, or haemodialysis). Before any clinical action: confirm the result is non-haemolysed and repeat if doubt exists — pseudohyperkalaemia from haemolysis is the most common cause of a single elevated potassium result and must be excluded before escalating treatment.

Normal

Serum potassium within the reference range (3.5–5.1 mEq/L) confirms normal extracellular potassium at the time of measurement in a non-haemolysed specimen. In patients at risk of potassium derangement — CKD, diuretic use, ACE inhibitor/ARB therapy, adrenal disease — a normal single potassium result confirms adequacy at that time point but does not preclude future derangement; serial monitoring frequency should be determined by clinical risk stratification. In functional medicine, a normal potassium in the lower half of the reference range (3.5–3.8 mEq/L) in a patient with cardiac risk factors may warrant supplementation optimisation to the 3.8–4.5 mEq/L functional optimal range.

Reduced

Hypokalaemia (serum potassium <3.5 mEq/L) requires clinical assessment of severity and aetiology. Mild hypokalaemia (3.0–3.4 mEq/L): commonly from diuretic use, gastrointestinal losses, or inadequate dietary intake — oral potassium supplementation is typically sufficient alongside addressing the cause. Moderate hypokalaemia (2.5–2.9 mEq/L): increased cardiac arrhythmia risk, particularly in patients with structural heart disease, digoxin use, or QT prolongation — oral or intravenous replacement depending on clinical urgency. Severe hypokalaemia (<2.5 mEq/L): critical value, potentially life-threatening arrhythmia risk — urgent intravenous potassium replacement with cardiac monitoring. Persistent hypokalaemia despite adequate replacement should prompt investigation for primary aldosteronism (renin-aldosterone ratio), Bartter or Gitelman syndrome, hypomagnesaemia (magnesium must be repleted for potassium repletion to succeed), and renal tubular acidosis.

Note: Haemolysis is the single most important clinical caveat for serum potassium — it is the most common laboratory artefact in routine clinical chemistry and produces the most clinically consequential false results of any common analyte. Every elevated serum potassium must be assessed for haemolysis on the Access Medical Laboratories report; a haemolysis index flagged alongside an elevated potassium should trigger mandatory recollection under optimal conditions before any clinical action is taken. A second fundamental caveat is that serum potassium reflects the extracellular pool only — representing approximately 2% of total body potassium — and can be normal despite significant total body potassium depletion, as occurs in chronic gastrointestinal losses or prolonged diuretic use where intracellular stores are depleted while serum potassium is maintained within range by renal and cellular compensatory mechanisms. The urinary potassium-to-creatinine ratio or transtubular potassium gradient (TTKG) are needed to determine whether the kidney is appropriately conserving or inappropriately wasting potassium in hypokalaemic patients.

Frequently asked questions

Serum potassium measures the concentration of potassium in the extracellular fluid — the fraction outside cells — which, despite representing only approximately 2% of total body potassium, is the dominant determinant of cardiac membrane potential and neuromuscular excitability. Deviations in either direction carry significant cardiac arrhythmia risk: hypokalaemia predisposes to ventricular ectopy and torsades de pointes; hyperkalaemia impairs cardiac conduction, producing a progressive ECG deterioration that can culminate in ventricular fibrillation or asystole at severe levels.

How to access the Serum Potassium test

The Serum Potassium reference page is free and open to all practitioners. Create a free practitioner account to see pricing, save tests to your list, and generate requisition forms. Verification takes 1–2 business days.

Create Free Account

About this page

Published: May 23, 2026

Last reviewed: May 23, 2026

References:

This content is for licensed healthcare practitioners only and does not constitute medical advice. Clinical decisions should be based on the full clinical picture and not on any single test result.

Related tests

metabolic diabetes

CMP

The Comprehensive Metabolic Panel is a 14-analyte serum chemistry panel simultaneously evaluating renal function (creatinine, BUN, eGFR), hepatic function (ALT, AST, total bilirubin, albumin, total protein), metabolic status (glucose, calcium), and electrolyte-acid-base homeostasis (sodium, potassium, chloride, bicarbonate) from a single fasting serum specimen.

BML-MET-003View reference →

vitamins minerals

Magnesium

Serum magnesium measures total circulating magnesium and is the validated first-line test for detecting acute magnesium disturbance, investigating refractory hypokalaemia or hypocalcaemia, and monitoring magnesium-wasting medications. Because under 1% of body magnesium is extracellular and serum levels are defended by tissue stores, a normal result does not exclude chronic total body depletion.

BML-VIT-011View reference →